Should I buy or sell OptimizeRx stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPRX shares. View OPRX analyst ratings or view top-rated stocks .

What is OptimizeRx's stock price target for 2024?

8 Wall Street research analysts have issued 1-year price targets for OptimizeRx's stock. Their OPRX share price targets range from $13.00 to $20.00. On average, they predict the company's share price to reach $15.60 in the next twelve months. This suggests a possible upside of 56.6% from the stock's current price. View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts .

How have OPRX shares performed in 2023?

OptimizeRx's stock was trading at $16.80 at the beginning of 2023. Since then, OPRX stock has decreased by 40.7% and is now trading at $9.96. View the best growth stocks for 2023 here .

When is OptimizeRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024. View our OPRX earnings forecast .

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) posted its earnings results on Monday, November, 6th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.09. The company had revenue of $16.33 million for the quarter, compared to analysts' expectations of $15.07 million. OptimizeRx had a negative trailing twelve-month return on equity of 9.24% and a negative net margin of 21.88%.

What ETFs hold OptimizeRx's stock?

ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD) . Global X Telemedicine & Digital Health ETF (EDOC) .

What guidance has OptimizeRx issued on next quarter's earnings?

OptimizeRx updated its FY 2023 earnings guidance on Monday, November, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $63.00 million-$65.00 million, compared to the consensus revenue estimate of $60.51 million.

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC) , Bank of Hawaii (BOH) , NVIDIA (NVDA) , STAG Industrial (STAG) , Etsy (ETSY) , Marvell Technology (MRVL) , Trade Desk (TTD) , Verizon Communications (VZ) , Advanced Micro Devices (AMD) and Amgen (AMGN) .

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Blair William & Co. IL (5.03%), AWM Investment Company Inc. (4.70%), Kennedy Capital Management LLC (3.34%), Rice Hall James & Associates LLC (2.33%), Jacob Asset Management of New York LLC (2.23%) and Federated Hermes Inc. (2.09%). Insiders that own company stock include Douglas P Baker, Douglas P Baker , Edward Stelmakh, Ellen O'connor Vos, James Paul Lang, Marion Odence-Ford, Miriam J Paramore , Patrick D Spangler , Stephen L Silvestro, Stephen L Silvestro and William J Febbo . View institutional ownership trends .

How do I buy shares of OptimizeRx?

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

OptimizeRx Stock Price, News & Analysis (NASDAQ:OPRX)

$9.96

+0.45 (+4.73%)

(As of 12/1/2023 ET)

Compare

Today's Range: $9.46
▼
$10.03
50-Day Range: $7.06
▼
$10.02
52-Week Range: $6.92
▼
$20.55

Volume: 235,431 shs
Average Volume: 170,592 shs
Market Capitalization: $180.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.60

OptimizeRx MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 56.6% Upside
$15.60 Price Target
Short Interest: Bearish
5.08% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.65) to ($0.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Computer And Technology Sector

384th out of 592 stocks

Business Services, Not Elsewhere Classified Industry

64th out of 86 stocks

3.5

Analyst's Opinion

Consensus Rating
OptimizeRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.60, OptimizeRx has a forecasted upside of 56.6% from its current price of $9.96.
Amount of Analyst Coverage
OptimizeRx has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.08% of the outstanding shares of OptimizeRx have been sold short.
Short Interest Ratio / Days to Cover
OptimizeRx has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in OptimizeRx has recently increased by 5.73%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
OptimizeRx does not currently pay a dividend.
Dividend Growth
OptimizeRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OPRX.

3.3

News and Social Media Coverage

News Sentiment
OptimizeRx has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Computer and Technology companies.
News Coverage This Week
MarketBeat has tracked 1 news article for OptimizeRx this week, compared to 1 article on an average week.
Search Interest
3 people have searched for OPRX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OptimizeRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.40% of the stock of OptimizeRx is held by insiders.
Percentage Held by Institutions
77.82% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for OptimizeRx are expected to grow in the coming year, from ($0.65) to ($0.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OptimizeRx is -12.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OptimizeRx is -12.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OptimizeRx has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About OptimizeRx Stock (NASDAQ:OPRX)

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow. The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems. In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was founded in 2006 and is headquartered in Rochester, Michigan.

OPRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OPRX Stock News Headlines

November 21, 2023 | finance.yahoo.com

Why OptimizeRx Corp. (OPRX) Might be Well Poised for a Surge

November 20, 2023 | finance.yahoo.com

How Much Upside is Left in OptimizeRx Corp. (OPRX)? Wall Street Analysts Think 47.72%

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 18, 2023 | morningstar.com

OptimizeRx Corp OPRX

November 14, 2023 | finance.yahoo.com

Industry Analysts Just Made A Massive Upgrade To Their OptimizeRx Corporation (NASDAQ:OPRX) Revenue Forecasts

November 13, 2023 | finance.yahoo.com

OptimizeRx Corporation (NASDAQ:OPRX) Q3 2023 Earnings Call Transcript

November 9, 2023 | markets.businessinsider.com

RBC Capital Keeps Their Buy Rating on OptimizeRx (OPRX)

November 6, 2023 | msn.com

OptimizeRx beats Q3 top and bottom line estimates; initiates FY24 and updates FY23 outlook

December 3, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 6, 2023 | finance.yahoo.com

OptimizeRx Reports Third Quarter 2023 Financial Results

November 6, 2023 | finance.yahoo.com

OptimizeRx Corp (OPRX) Reports Q3 2023 Earnings, Raises 2023 Guidance and Introduces 2024 Guidance

November 4, 2023 | finance.yahoo.com

Investors in OptimizeRx (NASDAQ:OPRX) from three years ago are still down 60%, even after 11% gain this past week

November 3, 2023 | benzinga.com

A Preview Of OptimizeRx's Earnings

November 3, 2023 | msn.com

OptimizeRx Q3 2023 Earnings Preview

October 30, 2023 | finance.yahoo.com

OptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

October 25, 2023 | finance.yahoo.com

OptimizeRx Announces Completion of Medicx Acquisition and Sets Third Quarter 2023 Conference Call for November 6, 2023, at 8:30 a.m. ET

October 13, 2023 | markets.businessinsider.com

OptimizeRx (OPRX) Receives a Buy from Lake Street

October 13, 2023 | finance.yahoo.com

OptimizeRx Corp. (OPRX) Surges 13.0%: Is This an Indication of Further Gains?

October 12, 2023 | markets.businessinsider.com

OptimizeRx’s Acquisition of Medicx Health: A Strategic Move Towards Enhanced Patient Marketing and Significant Growth

October 12, 2023 | msn.com

Digital Health Tech OptimizeRx's Acquisition of Medicx Health To Boost Earnings And Market Potential: Analyst

October 12, 2023 | finanznachrichten.de

OptimizeRx Corporation: OptimizeRx Announces Agreement to Acquire Medicx Health for $95 million to Expand its Omnichannel Reach to Consumers

October 12, 2023 | seekingalpha.com

OptimizeRx to acquire Medicx Health for $95M

October 8, 2023 | finance.yahoo.com

Should You Investigate OptimizeRx Corporation (NASDAQ:OPRX) At US$7.29?

September 26, 2023 | finance.yahoo.com

OptimizeRx Unveils a Significant Enhancement to its Omni-channel Healthcare Engagement Platform

September 21, 2023 | finance.yahoo.com

Are OptimizeRx Corporation (NASDAQ:OPRX) Investors Paying Above The Intrinsic Value?

August 24, 2023 | finance.yahoo.com

OptimizeRx Expands AI Powered Omnichannel Platform

August 20, 2023 | finance.yahoo.com

OptimizeRx Corporation (NASDAQ:OPRX) Analysts Just Trimmed Their Revenue Forecasts By 13%

See More Headlines

Receive OPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/03/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/13/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Business services, not elsewhere classified
Sub-Industry: N/A
Sector: Computer and Technology
Current Symbol: NASDAQ:OPRX
CUSIP: N/A
CIK: 1448431
Web: www.optimizerx.com
Phone: (248) 651-6568
Fax: 248-453-5529
Employees: 109
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.60
High Stock Price Target: $20.00
Low Stock Price Target: $13.00
Potential Upside/Downside: +56.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,440,000.00
Net Margins: -21.88%
Pretax Margin: -21.88%
Return on Equity: -9.24%
Return on Assets: -8.71%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.35
Quick Ratio: 11.35

Sales & Book Value

Annual Sales: $62.45 million
Price / Sales: 2.89
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.40 per share
Price / Book: 1.56

Miscellaneous

Outstanding Shares: 18,150,000
Free Float: 17,353,000
Market Cap: $180.77 million
Optionable: Not Optionable
Beta: 1.05

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. William J. Febbo (Age 54)
CEO & Director
Comp: $694.4k
Mr. Edward Stelmakh C.M.A. (Age 57)
M.B.A., CFO & COO
Comp: $547.05k
Mr. Andrew Jacob D'Silva
Senior Vice President of Corporate Finance
Mr. Todd Inman (Age 67)
Chief Technology Officer
Ms. Marion K Odence-Ford (Age 58)
General Counsel & Chief Compliance Officer
Comp: $428.12k
Maira Alejandra
Media Relations Manager
Ms. Sheryl Kearney
Human Resources Manager
Mr. Terence J. Hamilton (Age 58)
Senior Vice President of Pharma
Comp: $441.63k
Dr. Doug Besch (Age 41)
Chief Product Officer
Ms. Theresa Greco
Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

OPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell OptimizeRx stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPRX shares.
View OPRX analyst ratings or view top-rated stocks.
What is OptimizeRx's stock price target for 2024?: 8 Wall Street research analysts have issued 1-year price targets for OptimizeRx's stock. Their OPRX share price targets range from $13.00 to $20.00. On average, they predict the company's share price to reach $15.60 in the next twelve months. This suggests a possible upside of 56.6% from the stock's current price.
View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts.
How have OPRX shares performed in 2023?: OptimizeRx's stock was trading at $16.80 at the beginning of 2023. Since then, OPRX stock has decreased by 40.7% and is now trading at $9.96.
View the best growth stocks for 2023 here.
When is OptimizeRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our OPRX earnings forecast.
How were OptimizeRx's earnings last quarter?: OptimizeRx Co. (NASDAQ:OPRX) posted its earnings results on Monday, November, 6th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.09. The company had revenue of $16.33 million for the quarter, compared to analysts' expectations of $15.07 million. OptimizeRx had a negative trailing twelve-month return on equity of 9.24% and a negative net margin of 21.88%.
What ETFs hold OptimizeRx's stock?: ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD).Global X Telemedicine & Digital Health ETF (EDOC).

What guidance has OptimizeRx issued on next quarter's earnings?: OptimizeRx updated its FY 2023 earnings guidance on Monday, November, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $63.00 million-$65.00 million, compared to the consensus revenue estimate of $60.51 million.
What other stocks do shareholders of OptimizeRx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).
Who are OptimizeRx's major shareholders?: OptimizeRx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Blair William & Co. IL (5.03%), AWM Investment Company Inc. (4.70%), Kennedy Capital Management LLC (3.34%), Rice Hall James & Associates LLC (2.33%), Jacob Asset Management of New York LLC (2.23%) and Federated Hermes Inc. (2.09%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo.
View institutional ownership trends.
How do I buy shares of OptimizeRx?: Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OPRX) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial